Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

K. Johnson,B. Brooks,Jeffrey A. Cohen,C. Ford,J. Goldstein,R. Lisak,L. Myers,H. Panitch,J. Rose,R. Schiffer,T. Vollmer,L. Weiner,J. Wolinsky

Published 1995 in Neurology

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
1995
Venue
Neurology
Publication date
Unknown publication date
Fields of study
Medicine
Identifiers
PMID 7617181
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.
1994cited by this paper
T suppressor hybridomas and interleukin‐2‐dependent lines induced by copolymer 1 or by spinal cord homogenate down‐regulate experimental allergic encephalomyelitis
1993cited by this paper
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.
1992cited by this paper
Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation
1992cited by this paper
Failure of copolymer I to inhibit the human T‐cell response to myelin basic protein
1991cited by this paper
A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosis
1991cited by this paper
Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.
1991cited by this paper
Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.
1988cited by this paper
A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis.
1987cited by this paper
Human cellular immune response to copolymer I and myelin basic protein
1986cited by this paper
Rating neurologic impairment in multiple sclerosis
1983cited by this paper
Effect of treatment with Copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE).
1983cited by this paper
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
1983cited by this paper
Multiple sclerosis: Trial of a synthetic polypeptide
1982cited by this paper
Experimental Allergic Encephalomyelitis ‐ Susceptibility and Suppression
1981cited by this paper
Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE.
1979cited by this paper
Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomeylitis. Preliminary report.
1977cited by this paper
Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.
1974cited by this paper
In vivo and in vitro immunological cross‐reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis
1973cited by this paper

CITED BY

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial
2026cites this paper
A narrative review on the safety of glatiramer acetate in multiple sclerosis: focus on Europe
2025cites this paper
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis
2025cites this paper
Epigenetic and Mitochondrial Metabolic Dysfunction in Multiple Sclerosis: A Review of Herbal Drug Approaches and Current Clinical Trials
2025cites this paper
The epidemiology, pathology and pathogenesis of MS: Therapeutic implications
2025cites this paper
Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms
2025cites this paper
Effects of HLA-DRA, HLA-DQA1 and IL-6 Gene Variations to Glatiramer Acetate Resistance in Multiple Sclerosis Patients
2025cites this paper
Effect of Different Treatments on Retinal Thickness Changes in Patients With Multiple Sclerosis: A Review
2025cites this paper
Cost-Utility Analysis and Efficiency Frontier of Drugs Available in Brazil for the Treatment of Relapsing-Remitting Multiple Sclerosis.
2025cites this paper
Pragmatic Clinical Trials in Neurology
2025cites this paper
Multiple sclerosis-like manifestations in systemic autoimmune and inflammatory disorders: an update
2025cites this paper
Chemokines as therapeutic targets for multiple sclerosis: a spatial and chronological perspective
2025cites this paper
Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review
2024cites this paper
Dynamic Expansion and Contraction of Multiple Sclerosis T2-Weighted Hyperintense Lesions Are Present below the Threshold of Visual Perception
2024cites this paper
Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis
2024cites this paper
Comorbilidades en la esclerosis múltiple y su influencia en la elección del tratamiento
2024cites this paper
Do efficacy results obtained from randomized controlled trials translate to effectiveness data from observational studies for relapsing–remitting multiple sclerosis?
2024cites this paper
Right Brain: The Unraveling.
2024cites this paper
Multiple sclerosis and cancer: Navigating a dual diagnosis
2024cites this paper
A review of treatment of relapsing-remitting type of multiple sclerosis (RRMS)
2024cites this paper
Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines.
2024cites this paper
Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair
2024cites this paper
Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis
2024cites this paper
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
2024cites this paper
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?
2024cites this paper
Untackling the economics of multiple sclerosis: A systematic review of economic evaluations of disease-modifying therapies indicated for multiple sclerosis.
2024cites this paper
The Effects of Neuroactive Steroids on Myelin in Health and Disease
2024cites this paper
Antioxidant effects of resveratrol in granulocytes from multiple sclerosis patients
2024cites this paper
Neuroprotection by acrolein sequestration through exogenously applied scavengers and endogenous enzymatic enabling strategies in mouse EAE model
2024cites this paper
Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine
2024cites this paper
A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
2023cites this paper
An update on combination therapies for multiple sclerosis: where are we now?
2023cites this paper
Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.
2023cites this paper
The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists.
2023cites this paper
Use of Cells, Supplements, and Peptides as Therapeutic Strategies for Modulating Inflammation after Spinal Cord Injury: An Update
2023cites this paper
Disease Modifying Therapies in Multiple Sclerosis: A Review
2023cites this paper
Reinforcer pathology, probabilistic choice, and medication adherence in patients with multiple sclerosis.
2023cites this paper
Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration
2023cites this paper
The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis
2023cites this paper
Disease‐modifying therapies in multiple sclerosis: A focused review of rituximab
2023cites this paper
Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
2023cites this paper
How does neurovascular unit dysfunction contribute to multiple sclerosis?
2023cites this paper
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders
2023cites this paper
Reconsidering the route of drug delivery in refractory multiple sclerosis: Toward a more effective drug accumulation in the central nervous system
2023cites this paper
Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis: What Is the Future of Multiple Sclerosis Treatment?
2023cites this paper
Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis.
2023cites this paper
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis
2023cites this paper
Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs.
2023cites this paper
TnP Peptide Suppresses Experimental Autoimmune Encephalomyelitis (EAE) in a Preclinical Mouse Model
2022cites this paper
Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
2022cites this paper
Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
2022cites this paper
Escalation vs. Early Intense Therapy in Multiple Sclerosis
2022cites this paper
Synthesizing cross‐design evidence and cross‐format data using network meta‐regression
2022cites this paper
How to choose initial treatment in multiple sclerosis patients: a case-based approach
2022cites this paper
A Brief Review of Multiple Sclerosis Treatments
2022cites this paper
Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
2022cites this paper
Treatment of relapsing multiple sclerosis – recommendations of the Croatian Neurological Society
2022cites this paper
Updates and advances in multiple sclerosis neurotherapeutics
2022cites this paper
Treatment of Multiple Sclerosis
2022cites this paper
Neurodegeneration in multiple sclerosis
2022cites this paper
Comparative efficacy and safety of disease-modifying therapies in patients with relapsing multiple sclerosis: A systematic review and network meta-analysis.
2022cites this paper
Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
2022cites this paper
Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional study.
2022cites this paper
Comparative safety of high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis: a systematic review and network meta-analysis
2022cites this paper
Hiding in plain sight: The magnitude of unused disease modifying therapies in multiple sclerosis and strategies for reducing the economic burden of care.
2022cites this paper
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis
2022cites this paper
Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study
2022cites this paper
Predictors of Disease Activity and Worsening in Relapsing-Remitting Multiple Sclerosis
2022cites this paper
Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study
2022cites this paper
Thinking outside the box: non-canonical targets in multiple sclerosis
2022cites this paper
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies
2021cites this paper
Real-world experience of ocrelizumab in multiple sclerosis in an Arab population
2021cites this paper
Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.
2021cites this paper
Immunomodulation induced by central nervous system‐related peptides as a therapeutic strategy for neurodegenerative disorders
2021cites this paper
Outcomes of pregnancy in Egyptian women with multiple sclerosis in the new treatment era: a multi-center retrospective observational study
2021cites this paper
Effect of switching glatiramer acetate formulation from 20 mg daily to 40 mg three times weekly on immune function in multiple sclerosis
2021cites this paper
Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
2021cites this paper
The Role of Distinct Subsets of Macrophages in the Pathogenesis of MS and the Impact of Different Therapeutic Agents on These Populations
2021cites this paper
Review of the COVID-19 Risk in Multiple Sclerosis
2021cites this paper
Treatment options in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
2021cites this paper
The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis
2021cites this paper
Influence of Genetic Polymorphisms on Clinical Outcomes of Glatiramer Acetate in Multiple Sclerosis Patients
2021cites this paper
Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies
2021cites this paper
Efficacy classification of modern therapies in multiple sclerosis.
2021cites this paper
Diagnosis and Treatment of Multiple Sclerosis: A Review.
2021cites this paper
Trends in peptide drug discovery
2021cites this paper
Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
2021cites this paper
An emerging potential of metabolomics in multiple sclerosis: a comprehensive overview
2021cites this paper
Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care
2021cites this paper
Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis.
2021cites this paper
Type I interferon therapies of multiple sclerosis and hepatitis C virus infection
2021cites this paper
ANTI-CD20 THERAPY IN MULTIPLE SCLEROSIS-CLINICAL AND PARACLINICAL OUTCOMES
2021cites this paper
FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models
2021cites this paper
Satisfaction and adherence with glatiramer acetate 40mg/mL TIW in RRMS after 12 months, and the effect of switching from 20mg/mL QD.
2020cites this paper
In MS: Immunosuppression is passé.
2020cites this paper
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
2020cites this paper
Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis.
2020cites this paper
Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity
2020cites this paper
COMORBIDITY AND PERSISTENCE OF DISEASE-MODIFYING THERAPY USE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS by Natalie Elizabeth Parks Submitted in partial fulfilment of the requirements for the degree of Master of Science
2020cites this paper
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines.
2020cites this paper